IL6 and neoplasm: A recent study has highlighted the role of TAM-derived IL-6, particularly in EGFR mutant NSCLC, revealing that IL-6 can augment the immunotherapy resistance of tumor cells with EMT-associated resistance to EGFR-TKI (Wang et al., 2023).